Results 131 to 140 of about 14,626,039 (309)

Editorial: Psychological Aspects of Cannabis Use and Cannabis Use Disorder [PDF]

Frontiers in Psychiatry, 2021
Daniel Feingold, Eva Hoch, Eva Hoch, Aviv Weinstein, Wayne Hall   +4 more
openaire   +5 more sources

Continuous Intrajejunal Levodopa–Carbidopa Infusion in Parkinson's Disease Associated with 22q11.2 Deletion Syndrome: A Case Series

Movement Disorders Clinical Practice, EarlyView.
Abstract Background 22q11.2 deletion syndrome (22q11DS) is a multisystem genetic disorder associated with a significantly increased risk of early‐onset Parkinson's disease (EOPD). Management is challenging because psychiatric and cognitive comorbidities often limit advanced therapies such as deep brain stimulation (DBS). Cases We report 2 patients with
Valle Victor Andrés, Jardel Amory, Hopes Lucie, Clément Guillemette, Lambert Laetitia, Becker Aurélie, Dexheimer Mylène, Bonnet Céline, Frismand Solène, Renaud Mathilde, Puisieux Salomé   +10 more
wiley   +1 more source

Cannabis‐Based Oil for Pain and Other Non‐Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial

Movement Disorders, EarlyView.
Abstract Background There is a lack of treatments for non‐motor symptoms (NMS) in Parkinson's disease (PD). Objective To assess the safety and effectiveness of an oral Cannabis sativa L. extract on pain and other NMS of PD. Methods This phase II, randomized, placebo‐controlled trial evaluated a formulation containing cannabidiol (CBD; 96 mg/ml) and Δ9 ...
Gabriel T. Kubota, Jacy B. Parmera, Matheus Deltreggia, Pedro N. Martins, Anna Letícia M. Alves, Ananda C.M. de Falcone, Ana Rosa Santana, Maria Alice P. Falcão, Mayara A. Dias, Larissa I. Moreira, Paulo C. de Fonseca Filho, Eberval G. Figueiredo, Egberto R. Barbosa, Rubens G. Cury, Daniel C. de Andrade   +14 more
wiley   +1 more source

Factors associated with the use of cannabis for self-medication by adults: data from the French TEMPO cohort study

Journal of Cannabis Research
Background Medical cannabis, legalized in many countries, remains illegal in France. Despite an experiment in the medical use of cannabis that began in March 2021 in France, little is known about the factors associated with the use of cannabis for self ...
Solène Wallez, Isabelle Kousignian, Irwin Hecker, Selma Faten Rezag Bara, Astrid Juhl Andersen, Maria Melchior, Jean-Sébastien Cadwallader, Murielle Mary-Krause   +7 more
doaj   +1 more source

Deterrence effect of penalties upon adolescent cannabis use.

OBJECTIVE Penalties are used in an effort to curtail drug use by citizens in most societies. There are growing calls for a reduction or elimination of such penalties. Deterrence theory suggests that use should increase if penalties reduce and vice versa.
Smyth, Bobby P, Keenan, Eamon, Davey, Aoife   +2 more
core   +1 more source

Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies

Medicinal Research Reviews, EarlyView.
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva, Alessandra Aiello, Tonino Alonzi, M. Alice Carvalho, Vladimir Finger, Delia Goletti, Sven Hoffner, Yousra Kherabi, Jan Korabecny, Julia Kulczyńska, Agnieszka Kyzioł, Alicia Lacoma, Filomena Martins, Zorica Nanovic, Sepideh Hosseiniporgham, Martina Hrast Rambaher, Leonardo Antonio Sechi, Daria Smalchuk, Grażyna Stochel, Lydia Tabernero, Nancy L. Tateosian, Violeta Valcheva, Anamarija Zega, Mafalda Sarraguça   +23 more
wiley   +1 more source

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)‐VK4‐116, as a Non‐Opioid Medication for the Treatment of Opioid Use Disorder

Medicinal Research Reviews, EarlyView.
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu, Yu‐Chih Lin, Junfeng Huang, Bangwei Ding, Pramod Terse, Rahul Nandre, Haksong Jin, Molly Congdon, Kun Shen, Philip Sanderson, Gregory Tawa, Stephanie Mounaud, Marta De Santis, Donald Lo, Elizabeth A. Ottinger, Amy Hauck Newman   +15 more
wiley   +1 more source

Disparities in Synthetic Cannabis Use Among U.S. Adults, 2022–2024

Psychoactives
Synthetic cannabinoids are widely available in the United States, yet contemporary national data on who uses these products, and disparities in use, are limited.
Delvon T. Mattingly, Meman Diaby, Osayande Agbonlahor, Joy L. Hart   +3 more
doaj   +1 more source

The Mediating Role of Disengaged Coping in the Relationship Between Adverse Childhood Experiences and Substance Use Among Sexual Minority Adults

Research in Nursing &Health, EarlyView.
ABSTRACT Adverse childhood experiences (ACEs) are strongly linked to negative long‐term health outcomes. Sexual minority (SM) individuals face disproportionate exposure to ACEs and their consequences compared to heterosexual peers. However, the mechanisms connecting ACEs to these outcomes remain poorly understood.
Marvin A. Schilt‐Solberg, Julie J. A. M. J. Kurzer   +1 more
wiley   +1 more source

Understanding the presence of Cannabis across the Holocene in Central India

Quaternary Environments and Humans
Pollen records from sediment cores do not allow understanding of past human use of Cannabis because Cannabis may also grow naturally or increase incidentally in the presence of human settlements.
Meghna Agarwala, Charuta Kulkarni
doaj   +1 more source